Antibiotic treatment issues in patients with COVID-19

Area of Science:

• Infectious Diseases
• Public Health
• Pharmacology

Background:

• The COVID-19 pandemic presents a dual threat, potentially increasing antimicrobial resistance (AMR) and exacerbating the silent pandemic of multidrug-resistant organisms (MDROs).
• Antibiotic use in hospitalized COVID-19 patients has been prevalent, driven by concerns of bacterial co-infections, a pattern observed in previous viral respiratory outbreaks like H1N1, SARS, and MERS.
• Physician behavior and uncertainties surrounding COVID-19 have influenced prescribing patterns, leading to high rates of antibiotic administration, particularly in patients with mild to moderate illness.

Purpose of the Study:

• To critically evaluate the role and necessity of antibiotic treatment in patients hospitalized with COVID-19.
• To address the discrepancy between high antibiotic prescribing rates and the actual incidence of bacterial co-infections in COVID-19 patients.
• To provide guidance on appropriate antibiotic use in COVID-19 management based on disease severity.

Main Methods:

• Review of current literature and clinical guidelines regarding antibiotic use in COVID-19.
• Analysis of the incidence of bacterial co-infections and secondary infections in hospitalized COVID-19 patients.
• Comparison of observed antibiotic prescribing practices with World Health Organization (WHO) recommendations.

Main Results:

• The high frequency of antibiotic use in COVID-19 patients, especially those with mild to moderate disease, is not consistently supported by the incidence of bacterial co-infections.
• Antibiotic administration is often based on concerns or uncertainties rather than confirmed bacterial infections.
• The World Health Organization recommends antibiotic use primarily for severe or critical COVID-19 cases requiring intensive respiratory support.

Conclusions:

• A careful reassessment of antibiotic stewardship in COVID-19 is crucial to combat the growing threat of antimicrobial resistance.
• Antibiotic treatment should be reserved for patients with confirmed or highly suspected bacterial infections, particularly those with severe COVID-19 requiring intensive care.
• Optimizing antibiotic use in COVID-19 is essential to preserve the efficacy of existing antibiotics and mitigate the rise of multidrug-resistant pathogens.